Clinical Trial Update: Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial (PrEPSteps) evaluating ingestible biosensors to improve adherence to HIV PrEP in people who use substances has completed and posted resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Substance Use Disorder

Drugs mentioned

• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: HIV Infections, Substance Use Disorders | Phase 3 | Status: COMPLETED | Results posted: 2025-09-17